Neovacs S.A. (ALNEV) - Total Liabilities
Based on the latest financial reports, Neovacs S.A. (ALNEV) has total liabilities worth €4.10 Million EUR (≈ $4.79 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Neovacs S.A. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Neovacs S.A. - Total Liabilities Trend (2007–2025)
This chart illustrates how Neovacs S.A.'s total liabilities have evolved over time, based on quarterly financial data. Check Neovacs S.A. (ALNEV) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Neovacs S.A. Competitors by Total Liabilities
The table below lists competitors of Neovacs S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Clene Inc
NASDAQ:CLNNW
|
USA | $34.67 Million |
|
Hall of Fame Village LLC
NASDAQ:HOFVW
|
USA | $325.72 Million |
|
Lexaria Bioscience Corp
NASDAQ:LEXXW
|
USA | $1.53 Million |
|
Aquis Exchange PLC
LSE:AQX
|
UK | GBX7.47 Million |
|
BriaCell Therapeutics Corp
NASDAQ:BCTXW
|
USA | $3.35 Million |
|
Ucommune International Ltd
NASDAQ:UKOMW
|
USA | $173.94 Million |
|
immatics biotechnologies GmbH
NASDAQ:IMTXW
|
USA | $105.09 Million |
|
African Agriculture Holdings Inc.
NASDAQ:AAGR
|
USA | $41.77 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Neovacs S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Neovacs S.A. asset portfolio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neovacs S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neovacs S.A. (2007–2025)
The table below shows the annual total liabilities of Neovacs S.A. from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €4.10 Million ≈ $4.79 Million |
+2.32% |
| 2024-12-31 | €4.01 Million ≈ $4.69 Million |
+7.98% |
| 2023-12-31 | €3.71 Million ≈ $4.34 Million |
-26.53% |
| 2022-12-31 | €5.05 Million ≈ $5.91 Million |
+8.62% |
| 2021-12-31 | €4.65 Million ≈ $5.44 Million |
+85.71% |
| 2020-12-31 | €2.50 Million ≈ $2.93 Million |
-47.81% |
| 2019-12-31 | €4.80 Million ≈ $5.61 Million |
-0.06% |
| 2018-12-31 | €4.80 Million ≈ $5.61 Million |
-55.64% |
| 2017-12-31 | €10.82 Million ≈ $12.65 Million |
+33.98% |
| 2016-12-31 | €8.08 Million ≈ $9.44 Million |
+55.84% |
| 2015-12-31 | €5.18 Million ≈ $6.06 Million |
+48.65% |
| 2014-12-31 | €3.49 Million ≈ $4.08 Million |
-16.75% |
| 2013-12-31 | €4.19 Million ≈ $4.90 Million |
+61.63% |
| 2012-12-31 | €2.59 Million ≈ $3.03 Million |
+7.37% |
| 2011-12-31 | €2.41 Million ≈ $2.82 Million |
+0.39% |
| 2010-12-31 | €2.40 Million ≈ $2.81 Million |
-50.70% |
| 2009-12-31 | €4.88 Million ≈ $5.70 Million |
+122.67% |
| 2008-12-31 | €2.19 Million ≈ $2.56 Million |
+7.61% |
| 2007-12-31 | €2.04 Million ≈ $2.38 Million |
-- |
About Neovacs S.A.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IF… Read more